• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Yuzuru Kanakura, Kazuma Ohyashiki, +13 authors Mitsuhiro Omine
  • Medicine
  • International journal of hematology
  • 2011 (First Publication: 12 January 2011)
  • Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive and life-threatening disease characterized by complement-mediated chronic hemolysis, resulting in serious life-threatening complications andExpand
  • Chie Hirayama, Hiroshi Watanabe, +6 authors Hideyuki Saito
  • Chemistry, Medicine
  • Pharmaceutical Research
  • 2007 (First Publication: 1 April 2008)
  • PurposeThe purpose of this study was to investigate the contribution of drug transporters in acquired imatinib-resistance. Specifically, we focused on the efflux transporters, P-glycoprotein (P-gp)Expand
  • Yuji Yamakawa, Akinobu Hamada, +4 authors Hideyuki Saito
  • Medicine
  • Therapeutic drug monitoring
  • 2011 (First Publication: 1 April 2011)
  • This study explored the association of 14 single nucleotide polymorphisms in three genes coding for influx transporters (SLC22A1, SLCO1B1, and SLCO1B3), two genes coding for efflux transportersExpand
  • Elena Pokidysheva, Keith D. Zientek, +7 authors Hans Peter Bächinger
  • Medicine, Biology
  • The Journal of Biological Chemistry
  • 2013 (First Publication: 16 July 2013)
  • Background: 3-Hydroxylation of proline residues in type I collagen is rare but important. Results: 3-Hyp sites have been identified in both chains of mouse type I collagen in wild type and P3H1 nullExpand
  • Arinobu Tojo, Kensuke Usuki, +19 authors Tomoki Naoe
  • Medicine
  • International journal of hematology
  • 2009 (First Publication: 19 May 2009)
  • Nilotinib is a second-generation BCR-ABL kinase inhibitor with improved potency and selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to evaluate the efficacy, safety,Expand
  • Tatsuya Kawaguchi, Akinobu Hamada, +7 authors Hideyuki Saito
  • Medicine
  • International journal of hematology
  • 2009 (First Publication: 1 June 2009)
  • The standard dose of imatinib for the treatment of chronic-phase chronic myeloid leukemia (CML) is 400 mg/day. Some patients receive reduced doses of imatinib because of serious adverse effects.Expand